Regions – Page 2 – pharmaceutical daily

March 12, 2025 Off

CordenPharma & Viking Therapeutics Sign Long-Term Strategic Partnership for Integrated Supply of GLP-1 Peptides, Injectables & Oral Formulations

CordenPharma, a leading Contract Development & Manufacturing Organization (CDMO) specializing in the supply of peptide APIs and peptide-based therapeutic finished dosage drug products, is pleased to announce the signing of a strategic partnership with Viking Therapeutics, a clinical stage company focused on developing novel therapies for metabolic and endocrine disorders.

February 14, 2025 Off

Moderna reports full-year revenues of $3.2 billion, down from $6.8 in 2023 as Covid-19 vax sales drops

By Dino Mustafić

Moderna reports full-year revenues of $3.2 billion, GAAP net loss of $(3.6) billion and GAAP diluted EPS of $(9.28), and expects 2025 revenue range of $1.5 to 2.5 billion andending cash balance of approximately $6 billion.

February 13, 2025 Off

Barentz appoints new CFO

By Dino Mustafić

Barentz, a leading global specialty ingredients solution provider, has appointed Esther Veninga as Chief Financial Officer (CFO) and as a member of the Board.

February 13, 2025 Off

JuliaHub doubling investment in the pharmaceutical sector

By Dino Mustafić

JuliaHub is doubling its investment in the pharmaceutical sector, leveraging JuliaHub’s new-and-improved CFR Part 11-compliant pharmaceutical platform. The company said…

February 13, 2025 Off

Lindis grants Pharmanovia rights to market and spearhead its launch across Europe

By Dino Mustafić

Lindis Biotech GmbH, a clinical stage biopharmaceutical company, and Pharmanovia, a global pharmaceutical company, announced Thursday that catumaxomab has received marketing authorisation from the European Commission (EC), making the drug the only approved drug therapy for malignant ascites (MA) for patients living with this debilitating condition across Europe.

February 12, 2025 Off

Axplora announces €50 million investment in its Mourenx site, France

By Dino Mustafić

Axplora, a global leader in API small molecule and ADC manufacturing, has announced a landmark €50 million investment in its Mourenx site in Southwest France, securing its position as a key player in the fight against cardiovascular and metabolic diseases.

February 8, 2025 Off

One-time infusion of Hemgenix offers long-term durability, phase 3 HOPE-B trial shows

By Dino Mustafić

Global biotechnology company CSL Behring announced on Friday the four-year results from the pivotal HOPE-B study confirming the long-term durability…

February 7, 2025 Off

Ananda brings in new commercial adviser

By Dino Mustafić

Ananda Pharma (AQSE: ANA), is a UK-based developer of licenced, CBD-based medicinal products, has appointed Andy Rust as a commercial adviser, to provide the company with expert advice on its drug development and commercialisation plans.

February 3, 2025 Off

hVIVO, Inhalon Biopharma sign RSV human challenge trial contract

By Dino Mustafić

hVIVO has signed a contract with Inhalon Biopharma to assess its inhaled IN-002 antiviral candidate (“IN-002”) using the hVIVO Respiratory Syncytial Virus (RSV) Human Challenge Model.

February 3, 2025 Off

Roche gets FDA approval for the first companion diagnostic to identify patients with HER2-ultralow metastatic breast cancer eligible for ENHERTU

By GlobeNewswire

Roche announced Monday that the U.S. Food and Drug Administration (FDA) has approved a label expansion for the PATHWAY® anti-HER2/neu (4B5) Rabbit Monoclonal Primary Antibody* to identify patients with HR-positive, HER2-ultralow metastatic breast cancer who may be eligible for treatment with ENHERTU®.